UroStream

Non–muscle-invasive bladder cancer (NMIBC) carries a substantial risk of postoperative recurrence, particularly in high-risk and very high-risk patients, where the 5-year recurrence rate can exceed 50%. In recent years, beyond traditional Bacillus Calmette–Guérin (BCG) intravesical therapy, the emergence of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has provided new therapeutic options to reduce recurrence risk in high-risk NMIBC.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights into the integration of immunotherapy with radiotherapy. We invited Professor Aly-Khan A. Lalani from the Juravinski Cancer Centre at McMaster University, Canada, to discuss the study design, clinical implications, and future directions in the field.

The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an oral session, drawing significant international attention.

The 2026 European Association of Urology Annual Congress (EAU26), one of the most prestigious global meetings in urology, brought together leading advances in urologic oncology. Multiple studies on precision diagnosis of prostate cancer from the team led by Prof. Kan Gong and Prof. Yi Liu at Peking University First Hospital were selected for presentation, showcasing contributions from Chinese researchers on the international stage. Oncology Frontier invited Prof. Gong to share detailed insights into these findings.

During the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), a major breakthrough drew global attention: the first international external validation of the digital pathology–based AI predictive model MMAI in localized prostate cancer. Oncology Frontier – UroStream conducted an on-site interview with Prof. Anna Wilkins, Honorary Consultant in Clinical Oncology at The Institute of Cancer Research and The Royal Marsden Hospital (UK), who provided an in-depth interpretation of the study’s clinical value, real-world implementation prospects, and the broader advances highlighted at this year’s congress.

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), breakthroughs in the treatment of relapsed and refractory germ cell tumors emerged as a major focus in the field of genitourinary oncology. Oncology Frontier – UroStream invited Prof. Jennifer King from Indiana University School of Medicine for an in-depth interview, discussing her team’s key research findings, evolving trends in genitourinary cancers, and future directions in clinical development.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded, bringing forward several landmark advances in prostate cancer. Among them, the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial represent a major milestone in the management of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

From March 13–16, 2026, the 41st Annual Congress of the European Association of Urology (EAU26) was held at the ExCeL International Convention Centre in London, UK. As the largest and one of the most authoritative academic events in urology worldwide, the congress brought together leading experts from over 100 countries and regions to discuss cutting-edge advances and drive innovation in the field. At a featured scientific session, Prof. Ke Sun, representing the team led by Prof. Haixing Mai from the Chinese PLA General Hospital (301 Hospital), presented a study entitled:

With the publication of landmark studies such as EV302 and RC48-C016, the combination of antibody–drug conjugates (ADCs) and immunotherapy has firmly established its role as a new standard in the treatment of advanced urothelial carcinoma. Despite these advances, variability in clinical benefit remains evident, highlighting the need to identify more refined predictive biomarkers. 

The 41st Annual Congress of the European Association of Urology (EAU26) was recently held at the ExCeL International Convention Centre in London, UK. As one of the largest and most influential academic gatherings in global urology, the meeting brought together leading experts and scholars from over 100 countries and regions to discuss the latest advances and innovations in clinical practice.